International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma
Status:
Recruiting
Trial end date:
2027-10-31
Target enrollment:
Participant gender:
Summary
Primary objectives:
- Randomization R1, all patients eligible: To examine, whether the cumulative incidence of
relapses with involvement of the CNS (CNS relapse, pCICR) can be decreased by a modified
induction therapy including dexamethasone (experimental arm) instead of prednisone
(standard arm)
- Randomization R2, only patients with high risk LBL eligible: to examine, whether the
probability of event-free survival (pEFS) in these patients can be improved by receiving
an intensified treatment arm versus a standard treatment arm (as used in the EURO-LB 02)